GS
RCUS icon

Gilead Sciences’s Arcus Biosciences RCUS Stock Holding History

Gilead Sciences’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$679M Hold
31,424,760
– – 32.05% 2
2025
Q4 		$749M Hold
31,424,760
– – 38.69% 1
2025
Q3 		$427M Hold
31,424,760
– – 23.86% 3
2025
Q2 		$256M Hold
31,424,760
– – 19.98% 3
2025
Q1 		$247M Buy
31,424,760
+1,363,636
+5% +$15.8M 20.88% 3
2024
Q4 		$448M Buy
+30,061,124
New +$491M 28.86% 3

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gilead Sciences's RCUS Position: Q1 2026 in Review

Gilead Sciences held its Arcus Biosciences (RCUS) position steady in Q1 2026 at 31,424,760 shares worth $679M. The position accounts for 32.05% of the portfolio, ranked #2.

Gilead Sciences first reported a position in RCUS in Q4 2024 and has held it in 6 quarters since. The position peaked at $749M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Gilead Sciences held 31,424,760 shares of Arcus Biosciences worth $679M as of Q1 2026.
  • Gilead Sciences left its Arcus Biosciences share count unchanged in Q1 2026.
  • Arcus Biosciences made up 32.05% of Gilead Sciences's portfolio in Q1 2026, its #2 holding.
  • Gilead Sciences first reported a position in Arcus Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Gilead Sciences's Arcus Biosciences position peaked at $749M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Gilead Sciences's 13F filing for Q1 2026, filed 8 May 2026.